Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A case study on rheumatoid arthritis.

Tom Baker1

  • 1Strategy and Analytics Practice, The Zitter Group, Millburn, New Jersey, USA.

The American Journal of Managed Care
|October 7, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Importance of Shared Patient Voices in Advancing Science for Genodermatoses on a Global Scale.

The Journal of investigative dermatology·2025
Same author

Future Hospital Commission, 10 years on - Lessons learned and next steps: The Chief Registrar Programme - what has been achieved?

Future healthcare journal·2024
Same author

'Mentoring the Gap' for Junior Doctors: Promoting an under-utilised resource back to centre-stage.

MedEdPublish (2016)·2023
Same author

Typing myalgic encephalomyelitis by infection at onset: A DecodeME study.

NIHR open research·2023
Same author

Spatial, temporal and socioeconomic patterns of illicit drug use in New Zealand assessed using wastewater-based epidemiology timed to coincide with the census.

The New Zealand medical journal·2021
Same author

Graduates' perceptions of the role and availability of career guidance at medical school.

Irish journal of medical science·2021
Same journal

Prescription drug prior authorization: costs to pharmacies and physicians.

The American journal of managed care·2026
Same journal

Combined pharmacotherapy and psychotherapy impact on opioid use disorder treatment.

The American journal of managed care·2026
Same journal

The societal costs of food insecurity: implications for managed care strategies.

The American journal of managed care·2026
Same journal

Availability of hospital financial assistance documents in non-English languages.

The American journal of managed care·2026
Same journal

Real-world weight loss with injectable semaglutide vs dulaglutide for diabetes.

The American journal of managed care·2026
Same journal

Social needs screening and supplemental benefits in Medicare Advantage.

The American journal of managed care·2026
See all related articles

Biologic agents pose significant clinical and financial challenges for rheumatoid arthritis management. Traditional cost-sharing methods like tiered formularies may not be optimal for these advanced therapies.

Area of Science:

  • Rheumatology
  • Health Economics
  • Pharmacoeconomics

Background:

  • Managed care organizations increasingly utilize tiered formularies and copay differentials to manage drug costs.
  • Biologic agents present unique clinical and financial challenges in managing rheumatoid arthritis (RA).
  • Current cost-shifting strategies may be insufficient for optimal management of expensive biologic therapies.

Purpose of the Study:

  • To discuss the clinical and financial challenges posed by biologic agents in rheumatoid arthritis (RA) management.
  • To evaluate the suitability of traditional managed care strategies for biologic therapies.
  • To inform healthcare professionals on optimizing RA treatment with biologics.

Main Methods:

  • This article provides a discussion and analysis of existing literature and managed care practices.

Related Experiment Videos

  • It synthesizes information relevant to healthcare professionals and managed care decision-makers.
  • No primary data collection or experimental methods were employed; this is a review and discussion.

    • Main Results:

    • Biologic agents for RA are associated with substantial clinical benefits but also high costs.
    • Tiered formularies and increased patient cost-sharing may not adequately address the complexities of biologic therapy.
    • Optimal management requires strategies beyond simple cost-shifting.

    Conclusions:

    • Biologic agents for rheumatoid arthritis require specialized management approaches.
    • Relying solely on tiered formularies and patient cost-sharing is unlikely to be effective for these advanced treatments.
    • Healthcare professionals and managed care organizations must explore alternative strategies for cost-effective biologic RA therapy.